acetomycin: isolated from Streptomyces ranulosus; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 100162 |
| CHEMBL ID | 162264 |
| MeSH ID | M0137839 |
| Synonym |
|---|
| 3-acetyl-5-(acetyloxy)dihydro-3,4-dimethyl-2(3h)furanone |
| 2(3h)-furanone, 3-acetyl-5-(acetyloxy)dihydro-3,4-dimethyl- |
| brn 0174279 |
| nsc 350598 |
| nsc-350598 |
| 510-18-9 |
| acetomycin |
| NSC350598 , |
| [(2r,3s,4s)-4-acetyl-3,4-dimethyl-5-oxo-tetrahydrofuran-2-yl] acetate |
| (-)-acetomycin |
| 2(3h)-furanone, 3-acetyl-5-(acetyloxy)-dihydro-3,4-dimethyl-, (3s-(3alpha,4alpha,5alpha))- |
| [(2r,3s,4s)-4-acetyl-3,4-dimethyl-5-oxooxolan-2-yl] acetate |
| CHEMBL162264 |
| 373b64it09 , |
| 4-18-00-01135 (beilstein handbook reference) |
| unii-373b64it09 |
| 2(3h)-furanone, 3-acetyl-5-(acetyloxy)dihydro-3,4-dimethyl-, (3s,4s,5r)- |
| j479.514h , |
| 2(3h)-furanone, 3-acetyl-5-(acetyloxy)dihydro-3,4-dimethyl-, (3s-(3.alpha.,4.alpha.,5.alpha.))- |
| HB3734 |
| (2r,3s,4s)-4-acetyl-3,4-dimethyl-5-oxotetrahydro-furan-2-yl acetate |
| Q27256621 |
| (2r,3s,4s)-4-acetyl-3,4-dimethyl-5-oxooxolan-2-yl acetate |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Acetomycin has antitumor activity in vitro but not in vivo. " | ( Biological effects of acetomycin. II. Inactivation by esterases in vitro. Borondy, PE; Mamber, SW; Mitulski, JD; Tunac, JB, 1987) | 2.03 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (45.13) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||